Top Markets
#1 Islamic Coin Islamic Coin +151.53%
#2 Palladium Network Palladium Network +18.73%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#4 clBTC clBTC +12.16%
#5 OpenEden OpenEden +10.74%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.75%
#7 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.73%
#8 MarsCoin MarsCoin +8.66%
#9 Mantle Staked Ether Mantle Staked Ether +8.33%
#10 Mantle Restaked ETH Mantle Restaked ETH +8.01%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
PCI Biotech Holding ASA PCI Biotech Holding ASA

PCI Biotech Holding ASA

PCIB
Rank in Stocks #40012
PCI Biotech Holding ASA, an Oslo, Norway-based biopharmaceutical firm, is... PCI Biotech Holding ASA, an Oslo, Norway-based biopharmaceutical firm, is focused on pioneering and bringing to market innovative treatments for cancer. At the core of their operations is the proprietary photochemical internalization (PCI) technology platform. The company's development pipeline features several distinct therapeutic strategies: fimaCHEM, a novel approach to chemotherapeutic cancer treatment; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is currently in Phase I clinical studies; and fimaNAc, a delivery system for nucleic acid therapeutics, presently in its pre-clinical phase. Furthermore, they provide Amphinex, a photosensitizer known as fimaporfin. PCI Biotech actively participates in joint research endeavors with partners such as Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense.
Share Price
$0.00733708
Last synced: 2026-04-23
Market Cap
$273.87K
Change (1 day)
-39.13%
Change (1 year)
-94.83%
Country
NO
Trade PCI Biotech Holding ASA (PCIB)

Category

Healthcare
P/E ratio for PCI Biotech Holding ASA (PCIB)
P/E ratio as of 2026 TTM: 0
According to PCI Biotech Holding ASA latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for PCI Biotech Holding ASA from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.